

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



思路迪医药
3D Medicines

3D Medicines Inc.
思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

INSIDE INFORMATION

Announcement on The Arbitration Proceedings against SELLAS Life Sciences Group, Inc.

The announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to announce the latest significant progress in the dispute case involving SELLAS Life Sciences Group, Inc. (“**SELLAS**”). The case is under the full jurisdiction of Hong Kong International Arbitration Center. All evidentiary submissions and oral hearings have been completed, and a Final Award has been rendered following sole arbitrator deliberation.

After hearing the case, the sole arbitrator has dismissed all claims put forward by SELLAS. The tribunal further ordered SELLAS to bear the Company costs in the arbitration in the sum of HK\$7,983,004.42, which SELLAS is required to pay within 14 days from the date of the Award, i.e. by 7 August 2026. If SELLAS fails to fully settle all payable sums by the aforesaid deadline, interest at an annual rate of 8% shall be charged on any outstanding balance.

This arbitration shall not affect the performance of the Licence Agreement entered into between both parties. The Company will continue to progress the development and commercialization of 3D189 in Greater China in accordance with the terms of the Licence Agreement.

This announcement is released to notify the Company’s shareholders and potential investors of the latest corporate development of the Group. Shareholders and potential investors of the Company are reminded to exercise prudence when trading the Company’s securities.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, July 27, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.